Mirum Pharmaceuticals recently reported significant progress in its clinical trials, specifically with brelovitug showing strong antiviral activity and Volixibat demonstrating itch reduction. The stock saw a notable uptick, reflecting growing investor confidence as the company prepares for a critical EASL Congress presentation in May.
Mirum acquires Bluejay for up to $820 million, enhancing its product pipeline. The acquisition includes a late-stage drug targeting severe liver disease.
